Research programme: HCV polymerase inhibitors - Afea Pharmaceuticals

Drug Profile

Research programme: HCV polymerase inhibitors - Afea Pharmaceuticals

Alternative Names: AT 337; AT-511

Latest Information Update: 22 Mar 2017

Price : $50

At a glance

  • Originator Afea Pharmaceuticals
  • Class Purine nucleotides
  • Mechanism of Action Polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Hepatitis C

Most Recent Events

  • 11 Nov 2016 Pharmacokinetics and pharmacodynamics data from preclinical studies in Hepatitis C presented at the 67th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top